troglitazone has been researched along with Inflammation in 22 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 7.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| "Impressic acid, 3α,11α-dihydroxylup-20(29)-en-28-oic acid, is a lupane-type triterpenoid isolated from Acanthopanax koreanum, which has been used as a Korean folk medicine for rheumatism, hepatitis, diabetes, and inflammatory disorders." | 3.77 | Effects of impressic acid from Acanthopanax koreanum on NF-κB and PPARγ activities. ( Kim, JA; Kim, YH; Song, SB; Yang, SY, 2011) |
| "Peroxisome proliferator-activated receptor gamma (PPARgamma) plays a role in the regulation of intestinal inflammation and is activated by both natural (polyunsaturated fatty acid; PUFAs) and synthetic (troglitazone) ligands." | 3.74 | Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells--potential for dietary modulation of peroxisome proliferator-activated r ( Butler, M; Déchelotte, P; Ghosh, S; Marion-Letellier, R; Playford, RJ, 2008) |
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 3.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| "Female CD-1 (ICR) mice were given a single intraperitoneal administration of AOM (10 mg/kg body weight) and followed by one-week oral exposure of 2% (w/v) DSS in drinking water, and then maintained on the basal diets mixed with or without nimesulide (0." | 3.73 | Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. ( Kohno, H; Sugie, S; Suzuki, R; Tanaka, T, 2005) |
| " Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules." | 3.73 | Rosiglitazone ameliorates cisplatin-induced renal injury in mice. ( Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ, 2006) |
| "Sepsis is associated with impaired PMN function, including chemotaxis." | 1.35 | Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}. ( Keshamouni, VG; Milam, JE; Narala, VR; Newstead, MW; Reddy, RC; Standiford, TJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (81.82) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Quang, TH | 1 |
| Ngan, NT | 1 |
| Minh, CV | 1 |
| Kiem, PV | 1 |
| Tai, BH | 1 |
| Thao, NP | 1 |
| Song, SB | 2 |
| Kim, YH | 2 |
| Kim, SO | 1 |
| Han, Y | 1 |
| Ahn, S | 1 |
| An, S | 1 |
| Shin, JC | 1 |
| Choi, H | 1 |
| Kim, HJ | 1 |
| Park, NH | 1 |
| Kim, YJ | 1 |
| Jin, SH | 1 |
| Rho, HS | 1 |
| Noh, M | 1 |
| Reddy, RC | 1 |
| Narala, VR | 1 |
| Keshamouni, VG | 1 |
| Milam, JE | 1 |
| Newstead, MW | 1 |
| Standiford, TJ | 1 |
| Xiao, J | 1 |
| Leung, JC | 1 |
| Chan, LY | 1 |
| Guo, H | 1 |
| Lai, KN | 1 |
| Yokoi, T | 1 |
| Kim, JA | 1 |
| Yang, SY | 1 |
| Marx, N | 2 |
| Takata, Y | 1 |
| Kitami, Y | 1 |
| Yang, ZH | 1 |
| Nakamura, M | 1 |
| Okura, T | 1 |
| Hiwada, K | 1 |
| Okada, M | 1 |
| Yan, SF | 1 |
| Pinsky, DJ | 1 |
| Asada, K | 1 |
| Sasaki, S | 1 |
| Suda, T | 1 |
| Chida, K | 1 |
| Nakamura, H | 1 |
| Cheng, S | 1 |
| Afif, H | 1 |
| Martel-Pelletier, J | 1 |
| Pelletier, JP | 1 |
| Li, X | 1 |
| Farrajota, K | 1 |
| Lavigne, M | 1 |
| Fahmi, H | 1 |
| Reamy, BV | 1 |
| van Westerloo, DJ | 1 |
| Florquin, S | 1 |
| de Boer, AM | 1 |
| Daalhuisen, J | 1 |
| de Vos, AF | 1 |
| Bruno, MJ | 1 |
| van der Poll, T | 1 |
| Kohno, H | 1 |
| Suzuki, R | 1 |
| Sugie, S | 1 |
| Tanaka, T | 1 |
| Lee, S | 1 |
| Kim, W | 1 |
| Moon, SO | 1 |
| Sung, MJ | 1 |
| Kim, DH | 1 |
| Kang, KP | 1 |
| Jang, YB | 1 |
| Lee, JE | 1 |
| Jang, KY | 1 |
| Park, SK | 1 |
| Kim, WJ | 1 |
| Kim, JH | 1 |
| Jang, SK | 1 |
| Marion-Letellier, R | 1 |
| Butler, M | 1 |
| Déchelotte, P | 1 |
| Playford, RJ | 1 |
| Ghosh, S | 1 |
| Combs, CK | 1 |
| Johnson, DE | 1 |
| Karlo, JC | 1 |
| Cannady, SB | 1 |
| Landreth, GE | 1 |
| Hombach, V | 1 |
| Wada, K | 1 |
| Nakajima, A | 1 |
| Blumberg, RS | 1 |
| Marra, F | 1 |
| Pastacaldi, S | 1 |
3 reviews available for troglitazone and Inflammation
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro | 2002 |
19 other studies available for troglitazone and Inflammation
| Article | Year |
|---|---|
Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
Topics: Anti-Inflammatory Agents; Asarum; Cyclooxygenase 2; Dose-Response Relationship, Drug; Furans; Hep G2 | 2012 |
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
Topics: Adipogenesis; Adiponectin; Cinnamates; Dinoprostone; Humans; Inflammation; Keratinocytes; Matrix Met | 2018 |
Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}.
Topics: Actins; Anilides; Animals; Antineoplastic Agents; Cell Adhesion; Chemotaxis; Chromans; Disease Model | 2008 |
Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
Topics: Cells, Cultured; Chromans; Epithelial Cells; Female; Glomerulonephritis, IGA; Humans; Inflammation; | 2009 |
Current topics in drug metabolism and drug toxicity. Preface.
Topics: Chromans; Drug-Related Side Effects and Adverse Reactions; Humans; Inflammation; Pharmaceutical Prep | 2011 |
Effects of impressic acid from Acanthopanax koreanum on NF-κB and PPARγ activities.
Topics: Bone Marrow Cells; Cell Survival; Chromans; Cytokines; Dendritic Cells; Dose-Response Relationship, | 2011 |
PPARgamma and vascular inflammation: adding another piece to the puzzle.
Topics: Animals; CCAAT-Enhancer-Binding Protein-delta; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; Chr | 2002 |
Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma.
Topics: Animals; Carotid Arteries; CCAAT-Enhancer-Binding Protein-delta; CCAAT-Enhancer-Binding Proteins; Ce | 2002 |
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets.
Topics: Animals; Cell Line; Cell Movement; Chromans; Cytokines; DNA-Binding Proteins; Early Growth Response | 2002 |
Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages.
Topics: Apoptosis; CD36 Antigens; Chromans; Humans; In Vitro Techniques; Inflammation; Macrophages, Alveolar | 2004 |
Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1.
Topics: Amino Acid Motifs; Anilides; Binding Sites; Blotting, Western; Cell Division; Cell Nucleus; Chromans | 2004 |
Preventing the progression of diabetes mellitus.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents; Inf | 2005 |
Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
Topics: Actins; Animals; Cell Differentiation; Ceruletide; Chromans; Chronic Disease; Collagen; Disease Mode | 2005 |
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bezafibrate; Body Weight; Chromans; Col | 2005 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinica | 2006 |
Anti-inflammatory lipid mediator 15d-PGJ2 inhibits translation through inactivation of eIF4A.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arsenites; Chromans; Cyclopentanes; Cytoplasmic Granules | 2007 |
Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells--potential for dietary modulation of peroxisome proliferator-activated r
Topics: Blotting, Western; Caco-2 Cells; Cells, Cultured; Chromans; Dendritic Cells; Enzyme-Linked Immunosor | 2008 |
Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-S | 2000 |
PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis, Ulcerative; Crohn Disease; Disease Models, Ani | 2001 |